Pharmacogenomics
Ai L, Kim WJ, Demircan B, Dyer LM, Bray KJ, Skehan R, Massoll NA, Brown KD.
The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
Carcinogenesis. 2008 Jan 3; [Epub ahead of print]
Kato K, Iida S, Uetake H, Takagi Y, Yamashita T, Inokuchi M, Yamada H, Kojima K, Sugihara K.
Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer.
Int J Cancer. 2008;122(3):603-8.
Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JP.
Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel.
Cancer Res. 2007;67(23):11335-43.
Strathdee G.
Epigenetic markers and response to chemotherapy in cancer.
Dis Markers. 2007;23(1-2):43-9. Review.
Yanokura M, Banno K, Kawaguchi M, Hirao N, Hirasawa A, Susumu N, Tsukazaki K, Aoki D.
Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
Oncol Rep. 2007;17(1):41-8.
Additional Publications
Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF, Herranz M, Paz MF, Sanchez-Cespedes M, Artiga MJ, Guerrero D, Castells A, von Kobbe C, Bohr VA, Esteller M.
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.
Proc Natl Acad Sci U S A. 2006;103(23):8822-7.
Gagnon JF, Bernard O, Villeneuve L, Tetu B, Guillemette C.
Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer.
Clin Cancer Res. 2006;12(6):1850-8.
Sabharwal A, Middleton MR.
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
Curr Opin Pharmacol. 2006;6(4):355-63.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R.
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 2005;352(10):997-1003.
Szyf M, Pakneshan P, Rabbani SA.
DNA demethylation and cancer: therapeutic implications.
Cancer Lett. 2004;211(2):133-43. Review.
Hamilton JP, Sato F, Greenwald BD, Suntharalingam M, Krasna MJ, Edelman MJ, Doyle A, Berki AT, Abraham JM, Mori Y, Kan T, Mantzur C, Paun B, Wang S, Ito T, Jin Z, Meltzer SJ.
Promoter methylation and response to chemotherapy and radiation in esophageal cancer.
Clin Gastroenterol Hepatol. 2006;4(6):701-8.
Glasspool RM, Teodoridis JM, Brown R.
Epigenetics as a mechanism driving polygenic clinical drug resistance.
Br J Cancer. 2006;94(8):1087-92.
Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Penas R, Sanchez JM, Moran T, Camps C, Massuti B, Sanchez JJ, Salazar F, Catot S; The Spanish Lung Cancer Group.
14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
J Clin Oncol. 2005;23(36):9105-12.
Lyko F, Brown R.
DNA methyltransferase inhibitors and the development of epigenetic cancer therapies.
J Natl Cancer Inst. 2005;97(20):1498-506.
Altucci L, Clarke N, Nebbioso A, Scognamiglio A, Gronemeyer H.
Acute myeloid leukemia: Therapeutic impact of epigenetic drugs.
Int J Biochem Cell Biol. 2005;37(9):1752-62.
Strathdee G, Vass JK, Oien KA, Siddiqui N, Curto-Garcia J, Brown R.
Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.
Gynecol Oncol. 2005;97(3):898-903.
Digel W, Lubbert M.
DNA methylation disturbances as novel therapeutic target in lung cancer: Preclinical and clinical results.
Crit Rev Oncol Hematol. 2005;55(1):1-11.
Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Hofler H, Kiechle M, Klijn JG, Schmitt M, Maier S, Foekens JA.
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Cancer Res. 2005;65(10):4101-17.
Esteller M.
DNA methylation and cancer therapy: new developments and expectations.
Curr Opin Oncol. 2005;17(1):55-60.